Stocktoria
Strata Critical Medical, Inc. SRTA
Strata Critical Medical, Inc. (SRTA) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $197.1M at a 21.0% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -0.07 — elevated (above the −1.78 line — aggressive-accounting signals worth a closer look) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.327 |
| Retained earnings / assets | -0.447 |
| EBIT / assets | -0.069 |
| Equity / liabilities | 6.014 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| SRTA | Strata Critical Medical, Inc. | 4/9 | 6.54 | 11.1 | +34.3% |
| TALK | Talkspace, Inc. | 6/9 | 5.28 | 112.2 | +22% |
| OMDA | Omada Health, Inc. | 6/9 | 2.28 | — | +53.2% |
| DCGO | DocGo Inc. | 4/9 | -4.05 | — | -47.7% |
| VSEE | VSEE HEALTH, INC. | 3/9 | -16.83 | — | +40.3% |
| EUDA | EUDA Health Holdings Ltd | 5/9 | — | — | — |
| ATPC | Agape ATP Corp | 2/9 | 14.37 | — | — |
About Strata Critical Medical, Inc.
Strata Critical Medical, Inc. provides time-critical logistics and medical services to the healthcare industry in the United States. It operates in two segments, Logistics and Clinical. The company offers logistics services, such as air and ground transportation for human organs, transplant teams, and related medical materials and organ placement services; transplant clinical services, including organ recovery procedures, normothermic regional perfusion, and preservation services. It also provides other clinical services comprising cardiac perfusion services, blood management and autotransfusion services, extracorporeal membrane oxygenation services, perfusion staffing, and equipment rentals. The company was formerly known as Blade Air Mobility, Inc. and changed its name to Strata Critical Medical, Inc. in August 2025. The company was founded in 2014 and is headquartered in New York, New York.
FAQ
Is SRTA financially healthy?
Strata Critical Medical, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does SRTA pay a dividend?
No, Strata Critical Medical, Inc. does not currently pay a dividend.
How profitable is SRTA?
In FY2025, Strata Critical Medical, Inc. had a net margin of 21.0% and a return on equity of 14.8%.
What is SRTA's P/E ratio?
Strata Critical Medical, Inc.'s trailing price-to-earnings (P/E) ratio is about 11.1×, based on its latest annual earnings.
What is the analyst price target for SRTA?
The average Wall-Street price target for Strata Critical Medical, Inc. is $9.25, about 53.4% above the recent price, from 4 analysts (consensus: strong buy).
Is SRTA a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Strata Critical Medical, Inc.: a Piotroski F-score of 4/9, an Altman Z″ in the safe zone, a P/E of about 11.1×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.